OsciPulse D-dimer Pilot Trial

This is a single site, randomized open label two arm study. The patient population will be randomly divided into two arms, with one receiving the OsciPulse System and the other receiving standard intermittent compression therapy.

Both arms will have the therapy applied within 24 hours of admission and continue during their hospital stay until day 7 or discharge, whichever is shorter, unless clinically required to be removed. Daily d-dimer levels will be assessed until day 7 or discharge. If required beyond day 7, standard compression therapy will be provided. An interim analysis will be performed after 20 subjects are enrolled to evaluate the speed of enrollment and data variability and quality. If indicated, enrollment will be increased up to 40.

Inclusion criteria

• Adult aged ≥ 18 years old
• Admitted to the Neuro Intensive Care Unit or Intermediate Neuro Care Unit with a diagnosis of ischemic stroke
• < 24 hours from last known normal or treating-hospital admission.
• NIH stroke score ≥5
• Weakness in at least one leg (≥ 1 point on the NIHSS lower extremity motor scores)
• Prescribed mechanical therapy for DVT prophylaxis.

Exclusion criteria

• Inability or contraindication to applying IPC to both legs such as:

• Evidence of acute bone fracture in lower extremities
• Acute burns in the lower extremities, lacerations, ulcers, active skin infection or dermatitis, in the lower extremities at the site of IPC placement
• Acute ischemia or severe peripheral vascular disease in the lower extremities as evidenced by cyanotic, cool, pulselessness.
• Amputated foot or leg on one or two sides
• Compartment syndrome (acute injury causing swelling and ischemic injury)
• Severe lower extremity edema (+4 edema as documented by clinical team)
• Acute deep vein thrombosis 2. Subjects who received thrombolytic therapy for their stroke 3. Known pregnancy or within 6 weeks of postpartum period. 4. Limitation of life support, life expectancy < 7 days, or in hospice care 5. A head-unit is unavailable within 24 hours of study enrollment. 6. At the discretion of the attending physician and / or clinical team, the subject's participation in the study is believed not to be in the best interest of the subject.